SCHEMBL6760101

SCHEMBL6760101

CC(C)(C)OC(=O)N1CCCCC(NCc2ccc(NC(=O)OCc3ccccc3)cc2F)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.45
ANO1 Q5XXA6 2/20 0.42
RORC P51449 3/20 0.41
HRH3 Q9Y5N1 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TGM2 P21980 1/20 0.39
GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759997 0.94 USP30 (0.47) USP30PTGDR2RORCNPC1ALDH1A1
SCHEMBL6760105 0.82 USP30 (0.48) USP30PTGDR2RORCHRH3NPC1
SCHEMBL6760104 0.82 USP30 (0.48) USP30PTGDR2RORCHRH3NPC1
SCHEMBL13434239 0.79 USP30 (0.59) USP30ALDH1A1TSHR
SCHEMBL21295099 0.79 USP30 (0.59) USP30ALDH1A1TSHR
SCHEMBL28779720 0.79 USP30 (0.58) USP30BCHEACHEJAK2JAK1
SCHEMBL28779718 0.79 USP30 (0.58) USP30BCHEACHEJAK2JAK1
SCHEMBL21064049 0.79 USP30 (0.58) USP30ALDH1A1TSHR
SCHEMBL18391123 0.79 USP30 (0.58) USP30ALDH1A1TSHR
SCHEMBL6760005 0.78 JAK2 (0.49) USP30PTGDR2RORCJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147545-A1 Derivatives of oxazolidinones as antibacterial agents LABORATORIOS VITA, S.A. (ES) 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147545-A1 Derivatives of oxazolidinones as antibacterial agents OXA1L, Q6ZSR9, PGC USP30 4108/4885PTGDR2 1860/4885ANO1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.